Syncor expands PET market presence

Article

Radiopharmaceutical firm Syncor signed an agreement with Advanced Isotope to be the exclusive distributor for Advanced Isotope’s fluorodeoxyglucose (FDG) radioisotope used for PET. FDG will be produced by two new Advanced Isotope cyclotron

Radiopharmaceutical firm Syncor signed an agreement with Advanced Isotope to be the exclusive distributor for Advanced Isotope’s fluorodeoxyglucose (FDG) radioisotope used for PET.

FDG will be produced by two new Advanced Isotope cyclotron facilities in two Florida cities—Ft. Lauderdale and Ontario. Both new centers are set to open within three months.

Nashville-based Advanced Isotope produces the FDG used in the GE PET trace cyclotron system.

This agreement strengthens Syncor’s position in the PET market, said Robert Funari, Syncor’s president and CEO. The Woodland Hills, CA-based company has distribution agreements with PETNet Pharmaceutical Service, Massachusetts General Hospital, the University of Southern California, and the University of Texas.

In addition, Syncor, Isorad, and Sorec NRC, a branch of the Israeli government, will create an FDG production center to manufacture and distribute FDG in Israel. The use of PET in medical imaging is becoming more widely accepted because of increasing governmental approval.

In another example of that growing acceptance, Comprehensive Medical Imaging, A Syncor subsidiary, operates 43 PET imaging centers in Florida, Arizona, and Southern California. This year, CMI will open a new PET imaging center in Rancho Mirage, CA. Desert PET, as the facility will be called, will focus on CT and MR studies for cancer patients.

Syncor has received 510(k) clearance from the Food and Drug Administration for its palladium-103 seeds. The seeds are for use in treating localized prostate cancer (SCAN 2/2/00).

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.